A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma

Investigational New Drugs

Volumn 24, Issue 6, 2006, Pages 543-546

  Ronnen, Ellen A ^a   Kondagunta, G Varuni ^a   Ishill, Nicole ^a   Sweeney, Suzanne M ^a   DeLuca, John K ^a   Schwartz, Lawrence ^a   Bacik, Jennifer ^a   Motzer, Robert J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

17 AAG; Clear cell; Papillary; Renal cell carcinoma

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD TOXICITY; BRAIN METASTASIS; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DRUG DOSE REDUCTION; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; LIVER FUNCTION TEST; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MUSCLE WEAKNESS; MYALGIA; OPTIC NEURITIS; PAPILLARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; LACTAMS, MACROCYCLIC; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 33747691089     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9208-z     Document Type: Article

References (16)

1. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865-875
2. Motzer RJ, Rini, BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukoswki RM, George DJ, Kim ST, Baum CM (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). American Society of Clinical Oncology. vol. 23, Orlando, FL, p 380s
3. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24
4. Ratain MJE, Stadler WM, Flaherty KT, Gore M, Desai A, Patnaik A, Xiong HQ, Schwartz B, O'Dwyer P (2005) Final findings from a phase II placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). American Society of Clinical Oncology. vol. 23, no 16S, Orlando, FL, p 388s
5. Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170:2163-2172
6. Isaacs JS, Jung YJ,Mimnaugh EG,Martinez A, Cuttitta F, Neckers LM (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936-29944
7. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478-2482
8. Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60:342-349
9. Basso AD, Solit DB, Munster PN, Rosen N (2002) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159-1166
10. Burger AM, Fiebig HH, Stinson SF, Sausville EA (2004) 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15:377-387
11. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087
12. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885-1893
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
14. Stadler WM (2004) Therapeutic options for variant renal cancer: A true orphan disease. Clin Cancer Res 10:6393S-6396S
15. Schmidt L, Junker K, Nakaigawa N, Kinjerski T,Weirich G,Miller M, Lubensky I, NeumannHP, Brauch H, Decker J,Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B (1999) Novel mutations of the MET protooncogene in papillary renal carcinomas. Oncogene 18:2343-2350
16. Motzer RJ,Mazumdar M, Bacik J, BergW, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540